InnoPharma, Inc., a Piscataway, NJ-based developer of sterile generic and specialty pharmaceutical products, has completed a $15m Series A round of private financing.
The round was led by Thomas, McNerney & Partners.
The company intends to use the funding to accelerate the development of its product pipeline.
Led by Founder, President, and CEO Navneet Puri, Ph.D., InnoPharma has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities. The company works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.
In conjunction with the financing, Alex Zisson and James Thomas, both partners at Thomas, McNerney & Partners, have joined InnoPharma’s board of directors.
The board will also include Navneet Puri, Raman Kapur, the former CEO of Warrick Pharmaceuticals, and Peter Werth, the CEO of ChemWerth.